125 related articles for article (PubMed ID: 16887605)
1. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.
Yagi BH; Zurenko GE
Anaerobe; 1997 Oct; 3(5):301-6. PubMed ID: 16887605
[TBL] [Abstract][Full Text] [Related]
2. An in vitro time-kill assessment of linezolid and anaerobic bacteria.
Yagi BH; Zurenko GE
Anaerobe; 2003 Feb; 9(1):1-3. PubMed ID: 16887680
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
[TBL] [Abstract][Full Text] [Related]
4. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
[TBL] [Abstract][Full Text] [Related]
6. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
[TBL] [Abstract][Full Text] [Related]
8. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
Tyrrell KL; Citron DM; Warren YA; Fernandez HT; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
[TBL] [Abstract][Full Text] [Related]
10. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2009 Apr; 63(4):713-5. PubMed ID: 19164418
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT; Bryskier A
Antimicrob Agents Chemother; 2005 Jan; 49(1):408-13. PubMed ID: 15616322
[TBL] [Abstract][Full Text] [Related]
13. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
[TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activities of a novel oxazolidinone, OCID0050.
Paul-Satyaseela M; Solanki SS; Sathishkumar D; Bharani T; Magesh V; Rajagopal S
J Antimicrob Chemother; 2009 Oct; 64(4):797-800. PubMed ID: 19689978
[TBL] [Abstract][Full Text] [Related]
15. [Study of obligate anaerobic bacterial sensitivity to tinidazole and metronidazole (determination of minimal inhibiting concentration--MIC)].
Kałowski M; Dybicki J; Kedzia A; Lukiański M
Wiad Lek; 1993 Mar; 46(5-6):211-5. PubMed ID: 8249400
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
Srivastava BK; Soni R; Patel JZ; Solanki M; Valani D; Gupta S; Mishra B; Takale V; Pandya P; Jain MR; Patel PR
Bioorg Med Chem Lett; 2007 Sep; 17(18):5227-32. PubMed ID: 17624776
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of linezolid against clinical isolates of Fusobacterium spp.
Daeschlein G; Hoehne C; Assadian O; Daxboeck F; Meinl C; Kramer A; Kekulé AS
J Antimicrob Chemother; 2006 Oct; 58(4):789-93. PubMed ID: 16905529
[TBL] [Abstract][Full Text] [Related]
20. Tinidazole inhibitory and cidal activity against anaerobic periodontal pathogens.
Alou L; Giménez MJ; Manso F; Sevillano D; Torrico M; González N; Granizo JJ; Bascones A; Prieto J; Maestre JR; Aguilar L
Int J Antimicrob Agents; 2009 May; 33(5):449-52. PubMed ID: 19097755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
